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Abstract: This presentation will summarize ﬁve reports and
commissions released between July 2014-Feb 2015 that address
the response to the catastrophic Ebola epidemic in West Africa and
recommend changes to prepare better for future infectious disease
outbreaks, crises, and emergencies. The focus will be on World
Health Organization (WHO) reforms and actions by the United
Nations (UN). These reports and commissions include, but may not
be limited to: (1) July 7, 2015. Report of the Ebola Interim Assess-
ment Panel. Chaired by Dame Barbara Stocking. (2) Nov 22, 2015
published online in the Lancet. Moon S. et al. Will Ebola change
the game? Ten essential reforms before the next pandemic. The
report of the Harvard-LSTMH Independent Panel on the Global
Response to Ebola. (3) Jan 13, 2016. The Neglected Dimensions of
Global Security: A Framework to Counter Infectious Disease Crises.
Chaired by Peter Sands. (4) Jan 18, 2016 (Second and Final Report).
Advisory Group on Reform ofWHO’sWork in Outbreaks and Emer-
gencies. Chaired by Dr. David Nabarro. (5). Feb 2016 (anticipated
publication): The United Nations Secretary-General’s High-Level
Panel on the Global Response to Health Crises. While awaiting
implementation of much-needed WHO Reform, as revealed by the
Ebola catastrophe in West Africa, the emerging pandemic of Zika
virus, and possibly-related microcephaly, was recognized. Lucey
andGostin. The Emerging Zika Pandemic: Enhancing Preparedness.
JAMApublishedonline (Wednesday) Jan 27, 2016 (online) called on
the WHO Director-General to apply one of the most crucial lessons
that should have been learned from the delayed WHO response to
the Ebola epidemic in West Africa, and to no longer delay conven-
ing the WHO Emergency Committee to advise whether to declare a
Public Health Emergency of International Concern (PHEIC) related
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Abstract: The global MDR-TB caseload is increasingly driven by
primary transmission of MDR-TB in high burden countries. Control
will require interruption of transmission through earlier detection,
effectiveoutbreak investigation,detailed resistance testing toguide
tailored treatment for patients with highly resistant TB and devel-
opment and rapid access to better drugs. Genomics research and
the application of technologies enabled through genomic research
and technological innovation can play a critical role in each of these
areas. Early diagnosis is facilitated through rapid and sensitive
molecular detection of resistance-conferring mutations, real-time
whole genome sequencing is now being used to target outbreak
investigation and to rapidly identify resistance to second-linedrugs
and drug development has been enabled through the develop-
ment of sophisticated screening methods supported by genomic
tools. However, the promise of the genomic revolution has not yet
been translated to more effective control of MDR-TB, and signif-
icant obstacles and gaps in knowledge remain. This presentation
will highlight recent advances in this area, describe where exist-
ing genomic technologies are already being applied in MDR-TB
programmes and identify key knowledge gaps that remain.
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